• 1
    Amromin, G. D., Deliman, R. M., and Shanbrom, E.: Liver damage after chemotherapy for leukemia and lymphoma. Gastroenterology 42: 401410, 1962.
  • 2
    Arnold, H., and Bourseaux, F.: Synthese und abbau cytostatisch wirksamer cyclisher N-Phosphamidester des bis (B-chlorethyl-) amins. Angewandte Chemie 17/18: 539, 1958.
  • 3
    Aronovitch, M., Meakins, J. F., and Groszmon, M.: Use of cyclophosphamide in advanced malignancies. Can. Med. Assn. J. 83: 9971002, 1960.
  • 4
    Atkins, H. L., Gregg, G. H., and Hyman, G. A.: Clinical appraisal of cyclophosphamide in malignant neoplasms. Cancer 15: 10761080, 1962.
  • 5
    Bergsagel, D. E., and Levin, W. C.: A prelusive clinical trial of cyclophosphamide. Cancer Chemother. Rep. 8: 120134, 1960.
  • 6
    Bethell, F. H., Louis, J., Robbins, A., Donnelly, W. J., Dessel, B. H., Battle, J. D., JR., Pisciotta, A. V., Will, J., and Clifford, G. O.: Phase II Evaluation of cyclophosphamide—A study by the Midwest Cooperative Chemotherapy Group. Cancer Chemother. Rep. 8: 112115, 1960.
  • 7
    Burtner, O. W., Jensen, L. C., and Rumball, J. M.: Triethylene melamine in the treatment of lymphomas and other neoplastic disease. Ann. Intern. Med. 38: 12221244, 1953.
  • 8
    Coggins, P. R., Raudin, R. G., and Eisman, S. H.: Clinical evaluation of a new alkylating agent—Cytoxan (Cyclophosphamide). Cancer 13: 12541260, 1960.
  • 9
    Craver, L. F.: Treatment of chronic forms of malignant lymphomas and leukemias. Med. Clin. N. Am. 33: 527540, 1949.
  • 10
    Datta, H. S., Chandra, A. B., and Chowdhury, C. D. R.: Role of cyclophosphamide in the management of generalized malignant lymphomas. J. Indian Med. Assn. 43: 159163, 1964.
  • 11
    Dick, D. A. L., and Phillips, A. F.: Clinical experience with cyclophosphamide in malignant disease. Can. Med. Assn. J. 85: 974986, 1961.
  • 12
    DiPietro, S.: Sull'azione antineoplastica di un estere fosfamidico ciclico dell'iprite azotata (Endoxan, o B 518)—Esperienze cliniche. Minerva Med. 50: 34503454, 1959.
  • 13
    Doan, C. A., Wiseman, B. K., and Bouroncle, B. A.: Clinical evaluation of CB 1348 in leukemias and lymphomas. N.Y. Acad. Sci. 68: 979995, 1958.
  • 14
    Fernbach, D. J., Sutow, W. W., Thurman, W. G., and Vietti, T. J.: Clinical evaluation of cyclophosphamide—A new agent for the treatment of children with acute leukemia. JAMA 182: 3037, 1962.
  • 15
    Foley, J. F., and Kennedy, B. J.: Effect of cyclophosphamide (NSC-26271) in far-advanced neoplasia. Cancer Chemother. Rep. 34: 5558, 1964.
  • 16
    Foye, L. V., Chopman, C. G., Willett, F. M., and Adams, W. S.: Cyclophosphamide—A preliminary study of a new alkylating agent. Arch. Intern. Med. 106: 365367, 1960.
  • 17
    Gellhorn, A.: End-results in lymphosarcoma and Hodgkin's disease. In Proceedings of the Third National Cancer Conference, Philadelphia, J. B. Lippincott Co., 1957; pp. 862869.
  • 18
    Gross, V. R., and Lambers, K.: Erste Erfahrungen in der Behandlung maligner tumoren mit einem neuen N-Lost-Phosphamidester. Deutsche Med. Wschr. 83: 458463, 1958.
  • 19
    Haar, H., Marshall, G. J., Bierman, H. R., and Steinfeld, J.: The influence of cyclophosphamide upon neoplastic diseases in man. Cancer Chemother. Rep. 6: 4151, 1960.
  • 20
    Hall, C. A., and Olson, K. B.: Therapy of malignant lymphomas—I. A study of 116 cases. Am. J. Med. 20: 392398, 1956.
  • 21
    Höst, H., and Nissen-Meyer, R.: A preliminary clinical study of cyclophosphamide. Cancer Chemother. Rep. 9: 4750, 1960.
  • 22
    Israels, L. G., Galton, D. A. G., Till, M., and Wiltshaw, E.: Clinical evaluation of CB 1348 in malignant lymphoma and related diseases. Ann. N.Y. Acad. Sci. 68: 915925, 1958.
  • 23
    Karnofsky, D. A.: Triethylene melamine in the treatment of lymphomas and leukemias. Med. Clin. N. Am. 38: 541554, 1954.
  • 24
    Korst, D. R., Johnson, F. D., Frenkel, E. P., and Challener, W. L.: Preliminary evaluation of the effect of cyclophosphamide on the course of human neoplasms. Cancer Chemother. Rep. 7: 112, 1960.
  • 25
    Krebs, J., and Landes, E.: Zur endoxan therapie von malignen Wucherungen des reticulo-histocytären systems (Mycosis fungoides und Reticulosarkomatose). Der Hautarzt 16: 7678, 1965.
  • 26
    Laszlo, J., Grizzle, J., Jonsson, U., and Rundles, R. W.: Comparative study of mannitol mustard, cyclophosphamide and nitrogen mustard in malignant lymphomas. Cancer Chemother. Rep. 16: 247250, 1962.
  • 27
    Mathé, G., Schweisguth, O., Brulé, G., Schneider, M., Amiel, J. L., Schwarzenberg, L., and Cattan, A.: Essai de traitement par la cyclophosphamide de la leucémie aiguë lymphoblastique et du lymphoblastosarcome. Nouv. Rev. Franç. Hémat. 3: 480482, 1963.
  • 28
    Matthias, J. Q., Misiewicz, J. J., and Scott, R. B.: Cyclophosphamide in Hodgkin's disease and related disorders. Brit. Med. J. 2: 18371840, 1960.
  • 29
    Maxwell, G. M.: Twelve cases of lymphoblastomata in children. Arch. Dis. Child. 29: 155159, 1954.
  • 30
    Merrell, M., and Shulman, L. E.: Determination of prognosis in chronic disease—Illustrated by Systemic Lupus Erythematosus. J. Chron. Dis. 1: 1232, 1955.
  • 31
    Miller, D. G., Diamond, H. D., and Craver, L.: The clinical use of chlorambucil—A critical study. New Eng. J. Med. 261: 525535, 1959.
  • 32
    Papac, R., Petrakis, N. L., Amini, F., and Wood, D. A.: Comparative clinical evaluation of two alkylating agents—Mannitol mustard and cyclophosphamide (Cytoxan). JAMA 172: 13871391, 1960.
  • 33
    Philips, F. S., Steinberg, S. S., Cronin, A. P., and Vidal, P. M.: Cyclophosphamide and urinary bladder toxicity. Cancer Res. 21: 15771589, 1961.
  • 34
    Rosenberg, S. A., Diamond, H. D., Jaslowitz, B., and Craver, L. F.: Lymphosarcoma—A review of 1,269 cases. Medicine 40: 3184, 1961.
  • 35
    Rundles, R. W., Coonrad, E. V., and Willard, N. L.: Summary of results with TEM. Ann. N.Y. Acad. Sci. 68: 926936, 1958.
  • 36
    Rundles, R. W., Fulmer, J. W., and Opalinski, A.: Cyclophosphamide in cancer chemotherapy (abstr.). Proc. Am. Assn. Cancer Res. 3: 146, 1960.
  • 37
    Solomon, J., Alexander, M. J., and Steinfeld, J. L.: Cyclophosphamide—A clinical study. JAMA 183: 165170, 1963.
  • 38
    Stout, A. P.: Lymphosarcoma and Hodgkin's disease. R.I. Med. J. 32: 436439, 448, 1949.
  • 39
    Wall, R. L., and Conrad, Capt. F. G.: Cyclophosphamide therapy—Its use in leukemia, lymphoma and solid tumors. Arch. Intern. Med. 108: 456482, 1961.
  • 40
    Whitelaw, D. M., and Kim, H. S.: Vincristine in the treatment of neoplastic disease. Canad. Med. Assn. J. 90: 13851389, 1964.
  • 41
    Wintrobe, M. M., and Huguley, C. M.: Nitrogen mustard therapy for Hodgkin's disease, lymphosarcoma, the leukemias and other disorders. Cancer 1: 357382, 1948.